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Abstract
Current progress in the development of vaccines has decreased the incidence of fatal and non-fatal infections and increased
longevity. However, new technologies need to be developed to combat an emerging generation of infectious diseases.
DNA vaccination has been demonstrated to have great potential for use with a wide variety of diseases. Alone, this
technology does not generate a significant immune response for vaccination, but combined with delivery by
electroporation (EP), can enhance plasmid expression and immunity. Most EP systems, while effective, can be invasive
and painful making them less desirable for use in vaccination. Our lab recently developed a non-invasive electrode known
as the multi-electrode array (MEA), which lies flat on the surface of the skin without penetrating the tissue. In this study we
evaluated the MEA for its use in DNA vaccination using Hepatitis B virus as the infectious model. We utilized the guinea pig
model because their skin is similar in thickness and morphology to humans. The plasmid encoding Hepatitis B surface
antigen (HBsAg) was delivered intradermally with the MEA to guinea pig skin. The results show increased protein expression
resulting from plasmid delivery using the MEA as compared to injection alone. Within 48 hours of treatment, there was an
influx of cellular infiltrate in experimental groups. Humoral responses were also increased significantly in both duration and
intensity as compared to injection only groups. While this electrode requires further study, our results suggest that the MEA
has potential for use in electrically mediated intradermal DNA vaccination.
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Introduction
The development of vaccines is widely considered to be one of
the most important medical advancements of the 20
th century.
Current methods have been pushed to the limits of their potential.
New techniques need to be developed and employed to combat a
new generation of diseases and infections. There are several
advantages to DNA vaccination. DNA vaccines are cost effective
to produce, they can be easily stored, they are highly specific and
their multivalent nature means that they could be combined to
vaccinate against several different components simultaneously [1–
3]. Either due to low expression or lack of immune recognition,
injection of plasmid DNA alone does not elicit a strong enough
immune response for protective vaccination. Electroporation (EP)
is a non viral plasmid DNA delivery approach that effectively
enhances plasmid expression [4,5] and immunity [6–10].
EP requires the application of electric fields causing
permeabilization of the cell membranes. The permeabilized
membrane briefly contains ‘‘pores’’ that allow large molecules,
like DNA, to enter the cell. Initial studies evaluating in vivo EP
for transgene delivery and expression were performed on rat
brain tumors [5] and rat livers [4]. Those studies demonstrated
enhanced delivery and expression of plasmid DNA from EP
mediated delivery. Successful EP mediated DNA delivery has
been demonstrated in most tissue types and for several
therapeutic and prophylactic indications such as cancer therapy,
infectious diseases, wound healing, metabolic disorders and
vaccines [11]. Recently several clinical trials have been initiated.
Two clinical trials have been completed using EP, one assessing
tolerability of intramuscular delivery [12,13] and the other
assessing toxicity and clinical utility of delivering pIL-12
intratumorally by EP to melanoma patients [14]. The latter
demonstrated the safety, minimal toxicity, and feasibility for the
use of EP in the clinic [14]. Since the successful completion of
these studies, 19 others are currently active or recruiting. Five of
those are involving DNA vaccination against infectious agents
(clinicaltrials.gov; Keyword: Electroporation).
Initial in vivo EP DNA vaccine studies evaluated gene expression
and immune stimulation from delivery of plasmids encoding either
Hepatitis B Virus (HBV) protein or Human Immunodeficiency
Virus (HIV) protein, gag, to the muscle. Their results confirmed
that increased humoral responses to HBV [6] and cellular [9]
immune response to HIV gag from EP compared to injection only
(IO) of plasmid DNA. More recent studies have broadened the list
of pathogens which EP has been successfully used in vivo to include
other viral pathogens such as: Simian Immunodeficiency Virus
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[21–25], West Nile and Japanese Encephalitis [26,27], as well as
Hepatitis B and C [28–32] and Human Papilloma Virus [33,34].
EP delivered DNA vaccines expressing proteins of the parasitic
infection Plasmodium falciparum, one of the parasites causing malaria
[35], as well as bacterial infections like Bacillus anthracis [36],
Clostridium botulinum [37], and Mycobacterium tuberculosis [38] have
also been demonstrated to enhance immunogenicity. These results
demonstrate the capacity of EP to enhance not only gene delivery
and protein expression but also its ability to stimulate the host
immune response against a wide variety of pathogens.
Current electrically mediated DNA vaccines employ painful
invasive needle electrodes that are inserted into the muscle for
electrical stimulation. The primary tissue used for in vivo EP is
muscle because it is accessible, highly vascularized, multinucleated,
and expresses DNA for long periods of time due to the post-mitotic
nature of the tissue [39]. However, pain associated with
administration is not desirable. As such, alternative delivery sites
and methods have been explored. The skin is an attractive target
for vaccination because of the high proportion of antigen
presenting cells (APC) and large surface area. Recent studies, as
well as work done in our laboratory, demonstrated that
intradermal electrically mediated DNA expression can be
increased both locally and systemically [8,40–44]. Electrodes
developed for skin EP include: caliper, plate, tweezer, and clip
electrodes as well as several needle electrodes [14,45–48].
To develop an electrically mediated intradermal DNA vaccine
we utilized the non-invasive multi-electrode array (MEA), shown
in figure 1, for EP delivery. The MEA has 16 electrodes placed
2 mm apart and is arranged in 4 rows [45]. Pulses are
administered in a sequence that utilizes 4 electrodes at a time,
forming 262 mm squares (9 total squares). Pulses are applied in
pairs, in two directions, perpendicular to each other (18 pulses) for
4 rounds of pulsing (72 total pulses). While we have not as yet
modeled or directly measured the fields generated across the
treated area of skin, we believe by applying the field across a
smaller area (262 mm) will facilitate obtaining a more uniform
field then would be obtained when the field is applied across the
entire treated area (666 mm). Our lab previously demonstrated
that this electrode, when used in a guinea pig skin model, could
significantly increase reporter gene activity [45]. Conditions
required for optimal expression were determined to be between
200–300 V/cm and 150 ms.
An additional consideration for establishing a MEA delivered
DNA vaccine is choosing the appropriate animal model. Guinea
pig skin is similar to human skin in thickness and morphology [49].
For this reason, we selected the guinea pig model to better evaluate
our delivery approach utilizing a small animal model with skin
similar to humans. Therefore, the goal of this study was to evaluate
intradermal MEA EP delivery of Hepatitis B surface antigen in a
human-like skin model.
Methods
2.1 Ethics Statement
All animal procedures were conducted in a facility (USF) that is
fully accredited by the Association for the Assessment and
Accreditation of Laboratory Animal Care (AAALAC) and the
Public Health Service (PHS). Research was conducted under a
protocol approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of South Florida, College of
Medicine (protocol # 2879). All animals were housed, handled
and utilizing following guidelines of the United States National
Institutes of Health.
2.2 Animals
Female Hartley guinea pigs between 200–250 g were used in
this study to evaluate skin EP conditions. Guinea pigs were housed
at the University of South Florida, College of Medicine vivarium
and were rested for one week prior to experimentation. Guinea
pigs were anesthetized with 2.5–3.0% isoflurane before and during
all procedures. No previous exposure to Hepatitis B virus was
known. 2.2 Plasmid: The plasmid used in this study was gWiz
TM
HBsAg (Aldevron, Fargo, ND). This plasmid encodes for the
surface antigen of Hepatitis B and is driven by the CMV
promoter.
2.3 Immunization
All guinea pigs were intradermally injected with 100 mg (2 mg/
ml) of gWiz
TM HBsAg at two sites on the left flank. MEA EP was
performed at 300 V/cm and 150 ms and 72 pulses. The two
groups used in this study were control group injection of plasmid
only (IO) and injection of plasmid plus EP (I+EP). All groups were
boosted with the same condition at Day 14.
2.4 serum collection
Guinea pigs were bled through the jugular vein at various time
points from Day 0 through Day 168. Blood was collected and
serum isolated in serum separator tubes. Serum was diluted two-
fold starting at 1:10.
2.5 Tissue collection
Guinea pigs were treated as described with gWiz
TM HBsAg
with and without EP. Those guinea pigs whose tissue was collected
for plasmid expression were sacrificed 48 hours after one
Figure 1. Non-invasive Multi-Electrode Array. The MEA has 16
electrodes placed 2 mm apart and is arranged in 4 rows. Pulses are
administered in a sequence that utilizes 4 electrodes at a time, forming
262 mm squares (9 total squares). Pulses are applied in pairs, in two
directions, perpendicular to each other (18 pulses) for 4 rounds of
pulsing (72 total pulses). This image is reprinted from The Journal of
Controlled Release doi:10.1016/j.jconrel.2011.01.014 Siqi Guo, Amy
Donate, Guarav Basu, Cathryn Lundberg, Loree Heller, Richard Heller
‘‘Electro-gene transfer to the skin using a non-invasive multi-electrode
array’’ with permission from Elsevier.
doi:10.1371/journal.pone.0019181.g001
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treatment site and snap frozen. Those guinea pigs whose tissue
was collected to assess damage and cell infiltrate were treated and
harvested 96 hours after one treatment and the tissue was snap
frozen.
2.6 Indirect ELISA for the detection of Hepatitis B surface
antigen antibodies
The enzyme linked immunosorbant assay (ELISA) was used to
assess the production of antibodies from treatment and performed
per manufacturer’s protocol (Aldevron). Briefly, a 96-well plate
(Nunc) was coated with 10 mg/ml of Hepatitis B surface antigen
(Aldevron) and allowed to coat overnight at 4uC. The plate was
blocked with 3% BSA in PBST for 2 hours at 37uC. Serum
samples were two-fold diluted in blocking buffer and added to the
plate for 2 hours at 37uC. Goat anti-Guinea pig-AP antibody was
added at a 1:10000 dilution in blocking buffer. AP substrate,
pNPP, (Sigma) was added to colorize and the plate was read at
405 nm.
2.7 Immunohistochemistry
Pathological analysis of the skin sections was performed to
determine the extent of plasmid expression as well as inflammation
and tissue damage. An anti-HBsAg was used to detect plasmid
expression. Skin samples taken 48 hours after treatment were
frozen, sectioned, and placed on slides. Slides were rehydrated and
then blocked with 3% BSA in PBST and incubated in a
humidifying chamber for 1 hr. A HRP conjugated anti-HBsAg
(AbD Serotec) was made in blocking buffer at a 1:200 dilution. All
samples were counterstained with Hematoxylin & Eosin. Samples
collected at 96 hours frozen, sectioned, and placed on slides were
stained with H & E to determine the extent of cellular infiltrate/
inflammation.
2.8 Statistical analysis
All Guinea pigs were bled at Day 0 to determine background
optical density (OD). OD’s were averaged and 2 standard
deviations added to determine positive (0.1 OD). Experimental
serum samples were diluted two-fold starting at 1:10. End point
titers were calculated and plotted as Geometric Means. Signifi-
cance was determined by student t-test using the bonferroni
correction for multiple comparisons.
Results
3.1 Plasmid expression from EP
The first step in evaluating the MEA for delivery of DNA
vaccines in a human-like model was to determine the expression
levels of gWiz
TM HBsAg. Guinea pigs were treated as described
with or without EP using the MEA. 48 hours after delivery the
guinea pigs were euthanized and the treated skin harvested and
processed for histological evaluation. Expression of HBsAg was
determined by immunohistochemistry. Expression of HBsAg is
seen in IO and I+EP (Fig. 1a and b), however increased staining
was observed in the I+EP samples. Expression is contained within
the epidermis of IO animals. When compared to I+EP animals
expression can be seen within the epidermis and dermis.
3.2 Immune cell infiltrate and tissue damage
To determine whether EP with the MEA would recruit immune
cells to the treatment site and cause inflammation, guinea pigs
were treated as described and tissue samples harvested 96 hours
after treatment. Samples were stained with H&E to assess cellular
infiltrate, damage, and necrosis from treatment. The induction of
immune stimulation is important for vaccines in general, but can
be limited for DNA vaccines. Induction of immune cell infiltrate
was observed (Fig. 2 C–F 1006magnification). Background levels,
Fig. 2c, of infiltrate are demonstrated in no treatment control and
correspond to low levels of cellular infiltrate (purple). IO samples
show slight increases in infiltrate as compared to no treatment,
Fig. 2d. In contrast, I+EP samples show a large increase in cellular
infiltrate, Fig. 2e. I+EP groups contained primarily macrophages
and multi-lobed cells, most likely activated neutrophils (2006
magnification Fig. 2f), corresponding to a prolonged inflammatory
immune response [50].
Edema was seen in all samples except no treatment controls;
and did not appear increased due to EP. This is most likely a
result from the injection of plasmid into the tissue. In most
samples tissue damage and necrosis were not seen. However, two
EP delivered samples had minimal ulcerations at 96 hours after
treatment, one of which also had about 1% necrosis. There were
no other samples showing damage or necrosis (data not shown).
Gross evaluation of the skin shows no difference between IO and
I+EP groups over time (Fig. 3). Complete visual recovery of the
skin is seen by Day 7.
3.3 Anti-Hepatitis B surface antigen antibodies
While cellular infiltrate can be an early indicator of immunity,
a more accurate measure is the induction of specific antibodies
Figure 2. Plasmid expression and inflammation in the skin.
Guinea pigs were treated as described in Methods 2.1 with pHBsAg.
Expression of plasmid was evaluated at 48 hrs post treatment by IHC
(A-IO; B I+EP). Inflammation was measured 96 hrs post treatment and
assessed by H&E (C-No treatment; D- IO, E–I+EP) at 1006magnification
and 2006magnification (F- I+EP).
doi:10.1371/journal.pone.0019181.g002
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over time. Guinea pigs, treated and serum collected as described
in methods, showed significant increases in antibody expression
from three weeks after initial treatment through week 24. The
data collected was from 3 independent experiments (n=6 for
each experiement) with a total n of 18 for both IO and EP
groups. Peak expression for both groups occurred at week 18 with
IO groups having a GMT of 1000 and I+EP animals at 5000
(Fig. 4). The fold increase over IO remained relatively constant at
about 5 fold with the greatest fold increase over IO of 6.5
occurring at week 18.
Discussion
These data demonstrate that the MEA can be effective for the
use in electrically mediated DNA vaccination in a human-like skin
model. EP with the MEA generated increased plasmid expression
as well as an increase in immune infiltrate after treatment. The
magnitude of immune infiltrate was greater in EP groups than IO
and there was minimal to no skin damage associated. Specific,
lasting, and significant levels of antibodies were greater than IO.
This is the first report to demonstrate the use of the MEA for DNA
vaccination in a human-like skin model.
DNA vaccination is advantageous because it does not integrate
into the host DNA, it is cost effective to produce and easily stored,
it can be highly specific for tissue and/or cell type and can be
made to vaccinate against multiple agents simultaneously. The
skin is an ideal target for DNA vaccination due to the large
surface area and presence of antigen presenting cells like
langerhan’s and dermal dendritic cells, specialized for induction
of immunity [51].
However, injection of plasmid alone does not induce high
enough immune responses to be protective. EP is one method that
has been shown to increase both plasmid expression as well as
immunity. Previous EP methods have involved painful penetrating
electrodes that go into the muscle to facilitate delivery. Further
advancements have been made using non-penetrating electrodes
such as caliper and plate electrodes. However, these electrodes
require high voltages to enhance delivery and therefore can cause
tissue damage. In this study, we have evaluated a non-penetrating
electrode which reduces the gap width between electrodes to
2 mm thereby reducing the absolute voltage applied and
preventing visible tissue damage while still increasing plasmid
expression and immunity.
As expected from our previous publication [45], EP with the
MEA enhanced expression. While the exact reason for the
effectiveness of EP remains unknown, increased plasmid expres-
sion at least in the case of DNA vaccination, plays an important
role in recognition by the immune system [52]. EP has been shown
to have an adjuvant effect by recruiting immune cells to the site of
pulse application [53]. In our study, we saw an influx of nucleated
cells from EP treated samples. These cells are most likely
neutrophils and macrophages based on morphology. This is most
likely a combination of both an EP mediated adjuvant effect and
increased plasmid expression. The induction of macrophages and
polymorpho-nucleated neutrophils is indicative of a chronic
inflammatory response. While the perception of prolonged
inflammation is typically negative in our case it indicates that
the expression of the plasmid is present for a prolonged period of
time, giving the immune response enough time to perform its
function. Based on our earlier work [45] we would expect this
Figure 3. Visual assessment of skin damage and healing. Guinea
pigs were treated as described in Methods 2.1 with pHBsAg with or
without EP. Images were taken of skin pre treatment, immediately post
treatment, and at 24, 48, 72, 96 hours and at 7 days. Arrows indicate the
treatment sites.
doi:10.1371/journal.pone.0019181.g003
Figure 4. Evaluation of anti-HBs serum titer. Guinea pigs were
treated as described in Methods 2.1 with pHBsAg. Serum was collected
at multiple time points and an ELISA performed. Geometric mean titers
are expressed. Positive was determined by two standard deviations
greater than the Day 0 OD. IO and EP n=6 for each experiment with 3
independent experiments conducted (total n=18). Statistics were
determined by two-sided student t-test with bonferroni correction to
p,0.05.
doi:10.1371/journal.pone.0019181.g004
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therefore allowing the body to heal and not generate deleterious
effects from inflammation.
These findings seem to correlate with our antibody data, where
an increase in the presence of specific antibodies was measured
over time. These antibodies were significantly increased as
compared to injection only. Geometric mean titers ranged from
4000–16000 peaking at week 18. Antibody levels remained
elevated until dropping off after week 21, but still remained
increased as compared to injection only. The enhanced intensity of
humoral immunity by EP with the MEA corresponds to previously
published skin EP results [54–57]. One of the primary reasons for
evaluating our delivery method with Hepatitis B was because it is a
well characterized vaccination model. Published studies have
reported geometric mean titers in conjunction with protective
efficacy in guinea pigs. While the presented GMT’s in these papers
were higher than ours, they also reported protective levels more
than 100 fold above the necessary levels. Our GMT’s are likely to
still be within the protective range without generating unnecessary
additional responses [58,59]. Comparing specifically to Hepatitis B
DNA vaccines delivered by EP several animal models have been
evaluated and EP has been shown to have protective levels from
10–1000 mIU/ml [6,9,32,60,61]. The most recent comparable
publication evaluated a minimally invasive device for protective
vaccination against influenza [62]. While their results were only
presented as neutralizing titers against flu and cannot be compared
directly we believe that our electrode design generates immune
responses of equal quality without tissue penetration.
The data represented here demonstrate the capability of the
MEA to increase plasmid expression, immune cell infiltrate and
inflammatory response, as well as antibody production over 24
weeks in a human-like skin model. This information presents a
potential new method for DNA vaccination that may be
translatable to humans. Further studies will examine the MEA
for use in DNA vaccination against other infectious agents.
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